We found no overall significant heterogeneity across clinicopathological subgroups; however, of note is the results of the analyses showing that the influences of the age at menarche, duration of endogenous estrogen exposure, number of children, and number of years since last birth on breast cancer survival seemed to be more pronounced in HR+ HER2+ tumors (Fig 2). Here, ERBB2 is linked to breast cancer.